Michael Weller. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Antineoplastic Agents, Alkylating/adverse effectsAntineoplastic Agents, Alkylating/therapeutic useBrain Neoplasms/drug therapyBrain Neoplasms/radiotherapyBrain Neoplasms/secondaryBreast Neoplasms/drug therapyBreast Neoplasms/radiotherapyCarcinoma, Non-Small-Cell Lung/drug therapyCarcinoma, Non-Small-Cell Lung/radiotherapyCarcinoma, Non-Small-Cell Lung/secondaryCarcinoma, Small Cell/drug therapyCarcinoma, Small Cell/radiotherapyCarcinoma, Small Cell/secondaryChemotherapy, AdjuvantClinical Trials, Phase II as TopicCranial IrradiationDacarbazine/adverse effectsDacarbazine/analogs & derivativesDacarbazine/therapeutic useHumansLung Neoplasms/drug therapyLung Neoplasms/radiotherapyMelanoma/drug therapyMelanoma/radiotherapyMelanoma/secondaryMouth Neoplasms/drug therapyMouth Neoplasms/radiotherapyNeoplasms, Unknown Primary/drug therapyNeoplasms, Unknown Primary/radiotherapyRectal Neoplasms/drug therapyRectal Neoplasms/radiotherapyResearch DesignTemozolomideTreatment Outcome
Substances： See more » Antineoplastic Agents, AlkylatingDacarbazineTemozolomide
Year: 2007 PMID： 17596741 DOI： 10.1159/000103366
Source DB: PubMed Journal: Onkologie ISSN： 0378-584X